ReviewJournal of advanced research2025
FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems.
Review in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fibroblast growth factors in ischemic stroke: Therapeutic potential and clinical challenges.Acta pharmacologica Sinica · 2026Review
- Review
- Identification of circulatory neuro-related proteins in Parkinson's disease: an integrated genetic-proteomic-clinical study.EBioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast Growth Factors and Fibroblast Growth Factor Receptors (FGFs/FGFRs) constitute a complex and diverse signaling system crucial in various biological processes, such as cell proliferation, differentiation, migration, and survival. Dysregulation of the FGFs/FGFRs system plays a key role in the progression of neurological diseases through the neuroinflammatory process. FGFs/FGFRs have become a key target of novel drugs in recent years for the treatment of neurological diseases. Notably, drug delivery systems can enhance the clinical therapeutic efficacy of these drugs. AIM OF REVIEW: This review highlights the critical role of FGFs/FGFRs in various neuroinflammatory diseases and provides an overview of the current research on FGFs/FGFRs-targeted therapeutic drugs, their novel delivery systems, and development potential. Advances in this field can enhance further application of potential drugs, offering new insights and approaches for treating neuroinflammatory diseases, thus reducing the incidence and progression. KEY SCIENTIFIC CONCEPTS OF REVIEW: Moreover, this review summarizes the structure and function of FGFs/FGFRs, elucidates the signaling pathways through which the FGFs/FGFRs system is involved in neuroinflammatory diseases (Alzheimer's disease (AD) and Parkinson's disease (PD)), and emphasizes the key role of FGFs/FGFRs system in disease progression. Furthermore, the current anti-inflammatory drugs targeting the FGFs/FGFRs system, including direct FGF modulators and indirect FGF modulators, have been summarized. The positive impact of the development of novel drug delivery systems, such as liposomes, microspheres, and hydrogels, on therapeutic outcomes has also been discussed. Therefore, this review may offer guidance and insights for the management of neuroinflammatory disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.